Artificial AIM protein slows fatal feline kidney disease in trials
Artificial AIM protein cut feline kidney disease deaths in early trials, with treated cats showing 80% to 83% one-year survival versus 20% untreated.
Feline kidney disease is where the real significance of this work begins. Chronic kidney disease is one of the most prevalent illnesses in older cats, and Cornell’s Feline Health Center says it affects up to 40% of cats older than 10 and 80% of those older than 15. Against that backdrop, an artificial AIM protein has shown enough promise in early testing to move from lab concept to regulatory filing in Japan.
The treatment comes from Toru Miyazaki, the AIM discoverer and a former University of Tokyo professor, through the Tokyo-based Institute for AIM Medicine. IAM says AIM was discovered in 1999 and that cats are unusually vulnerable because their AIM cannot properly detach from IgM, which leaves the protein unable to reach the kidneys and help clear waste. That biological defect is the core of the disease story, not the marketing line about cats living to 30.
The early trial was conducted at 26 veterinary hospitals across Japan and began on June 13, 2025, according to IAM. In the results described by AFP and Phys.org, Miyazaki said 11 treated cats and 15 untreated cats were followed for a year. The cumulative survival rate in the treated group was 80% to 83%, compared with 20% in the untreated group. That is not a cure, and it is not a finished commercial product, but it is a sharp enough difference to suggest the therapy slowed the disease in a clinically meaningful way.
IAM later said it filed for manufacturing and marketing approval with Japan’s agriculture ministry on April 24, 2026. The institute has said the medicine could reach market by 2027, which would make this one of the most advanced protein-based veterinary therapies aimed at kidney failure in cats.
The program’s path has been anything but smooth. IAM said the project nearly stalled during the COVID-19 pandemic because of funding shortages, then restarted after cat lovers donated nearly 300 million yen between 2021 and 2022. The institute also pointed to support from corporate and fan donations, including a major contribution from Cygames Inc. and charity work tied to Felissimo’s cat club.
The larger value here may go beyond feline medicine. IAM has framed the work as a protein-therapy platform with human relevance, pointing to recent AIM/CD5L research on human protein structure and autoimmune arthritis. A treatment that can slow kidney failure in cats, in other words, could end up mattering well outside the cat clinic.
This article was produced by Prism’s automated news system from verified source data, official records, and press releases, then run through automated quality and moderation checks before publishing. The system is built and supervised by the people who set the standards it runs under. Read our full AI policy.
Did this article answer your question?
